NASDAQ:ABCL (AbCellera Biologics Inc.)
About ABCL
AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology.
Financial Market Data copyright © 2025
QuoteMedia. Data delayed 15 minutes unless otherwise
indicated (view
delay times for all exchanges).
RT=Real-Time, EOD=End of Day,
PD=Previous Day. Market
Data powered by QuoteMedia.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Profiles by Morningstar.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Financials by Morningstar.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia. Data delayed 15 minutes unless otherwise
indicated (view
delay times for all exchanges).
RT=Real-Time, EOD=End of Day,
PD=Previous Day. Market
Data powered by QuoteMedia.
Terms of Use.
Financial Market Data copyright © 2025
QuoteMedia. Data delayed 15 minutes unless otherwise
indicated (view
delay times for all exchanges).
RT=Real-Time, EOD=End of Day,
PD=Previous Day. Market
Data powered by QuoteMedia.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Share Information by Morningstar.
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Dividends by EDI/Mergent (USA) and TSX (CDN).
Terms of Use.
Financial Market Data copyright © 2022
QuoteMedia.
Market Data powered by
QuoteMedia. Earnings and Analyst Ratings by Zacks.
Earnings Events by Wall Street Horizon.
Terms of Use.
AbCellera Biologics Inc. (NASDAQ: ABCL) Latest News
Investing
The Best Canadian Stock You’ve Never Heard of
Tech Stocks
These Canadian Biotech Stocks Are Quietly Changing the Face of Healthcare
Investing
AbCellera Biologics Stock: Here’s What’s Coming in 2023
